WHAT WE DO
(since 2004 we have....)
· Enabled over 1200 people with MS to be involved in research studies.
· Our trustees see people with MS all the time.
· Our trustees see people with MS all the time.
COLLABORATION
· We are working with people in MS day to day but realise that collaborations are how we can identify, support and develop innovative ideas. Working with other groups has allowed us to bring some real change in novel areas.
· We have generated nearly £6.4million in income increasing the funds generated 14-fold for an investment of £450k+535 by an original investor.
· Running our own trial: we designed and implemented a 140 subject national phase II three-centre trial looking at the effect of high-dose Statins in Secondary Progressive MS (SPMS). The work involves collaboration with Prof Nick Fox, Prof Chris Frost (UCL), Prof John Greenwood (Institute of Ophthalmology, UCL), Nadine Scheurer (PhD student, UCL) and Dr Dennis Chan (University of Sussex).
· Infrastructure to enter people into trials: with Dr Paolo Muraro (Imperial) we have being funded by the MRC to prospectively collect a cohort of 200 patients with rapidly evolving MS. This group is uniquely suited both to fill an unmet healthcare need in MS and to bridge a gap that exists between patients and clinical and translational research.
· Forefront of global trials: we have gained funds (MS Society/UK Stem cell Foundation) to perform a trial in mesenchymal stem cells in MS. Collaborations are with Prof Miller (UCL), Prof Chandran (University of Edinburgh) and Prof Dazzi (Imperial). These have great potential not only to reduce inflammation but also repair damage. This is part of a global study of 160 subjects run by Anthony Ucelli (University of Genoa, Italy) and Prof Mark Freedman (University of Ottowa, Canada).
· We have generated nearly £6.4million in income increasing the funds generated 14-fold for an investment of £450k+535 by an original investor.
· Running our own trial: we designed and implemented a 140 subject national phase II three-centre trial looking at the effect of high-dose Statins in Secondary Progressive MS (SPMS). The work involves collaboration with Prof Nick Fox, Prof Chris Frost (UCL), Prof John Greenwood (Institute of Ophthalmology, UCL), Nadine Scheurer (PhD student, UCL) and Dr Dennis Chan (University of Sussex).
· Infrastructure to enter people into trials: with Dr Paolo Muraro (Imperial) we have being funded by the MRC to prospectively collect a cohort of 200 patients with rapidly evolving MS. This group is uniquely suited both to fill an unmet healthcare need in MS and to bridge a gap that exists between patients and clinical and translational research.
· Forefront of global trials: we have gained funds (MS Society/UK Stem cell Foundation) to perform a trial in mesenchymal stem cells in MS. Collaborations are with Prof Miller (UCL), Prof Chandran (University of Edinburgh) and Prof Dazzi (Imperial). These have great potential not only to reduce inflammation but also repair damage. This is part of a global study of 160 subjects run by Anthony Ucelli (University of Genoa, Italy) and Prof Mark Freedman (University of Ottowa, Canada).
GRANTS
The opportunity exists to apply for grants and we welcome applications for review by the charity's board of trustees. Grant applications are welcome from any institution/organisation relevant to the research area.
All applications are reviewed by an external panel of expert peer reviewers (panel members are selected for their expertise in the specific field of research under review); however, where a member of the external expert review panel holds a post at the same organisation as an applicant they do not take part in the decision making process.
Further information about the process can be found by downloading the PDF document below:
All applications are reviewed by an external panel of expert peer reviewers (panel members are selected for their expertise in the specific field of research under review); however, where a member of the external expert review panel holds a post at the same organisation as an applicant they do not take part in the decision making process.
Further information about the process can be found by downloading the PDF document below:
| grant_app_2013_final.pdf |
The charity and its trustees have directly awarded or been instrumental in the following grants/projects:
- Multiple Sclerosis Clinical trials unit development, Berkeley Homes,
£535,000 - UK Multiple Sclerosis Tissue Bank, MS Society,
£1,460,000 - Characterisation of multiple sclerosis immune parameters in West London patients of South Asian descent, Hammersmith Hospitals Charitable Trust,
£10,000 - Database development/clinical trials unit in Multiple Sclerosis at Hammersmith Hospitals NHS Trust, Smith Kline Beecham,
£70,000 - Statins in secondary progressive multiple sclerosis (MS_STAT Trial), The Moulton Charitable Foundation,
£325,000 - The role of white and grey matter and meningeal inflammation in MS and clinically isolated syndromes (CIS) as quantified
using [(11)C](R)-PK11195 positron emission tomography (PET) scanning‟, MRC funded with Paola Puccini. London MS register, AIMS2CURE,
£94,265 - Adaptive clinical trial design for treatment selection and evaluation in MS, MS Society, Lead applicant Prof Nigel Stallard,
£88,000
website: http://www.warwick.ac.uk/go/ms_adaptive - Rapidly evolving multiple sclerosis: opening the window of therapeutic opportunity, MRC Patient Research Cohorts Initiative, Lead applicant Paolo Muraro,
£509,180 - The role of HLA genes in South Asian multiple sclerosis, MS Society Innovative Award,
£123,000 - Natural Killer cell function in MS and other neuroinflammatory diseases, Saudi Government,
£186,504. - Role of relapses and additional prognostic factors in determining the long-term outcome
in MS, Italian Multiple Sclerosis, Foundation (FISM),
£41,381 - Functional relevance of haematopoietic stem cell mobilisation following therapeutic alpha 4-integrin blockade in multiple
sclerosis, MSTC,
£10,000 - The role of white and grey matter and meningeal inflammation in MS and clinically isolated syndromes (CIS) as quantified using [(11)C](R)-PK11195 positron emission tomography (PET) scanning, European federation of neurological sciences, Dr Paolo Gianetti,
€19,200 - UK Parkinsons Disease and Multiple Sclerosis Tissue Bank, PD/MS Society,
£2,055,691 - 'HLA-C, killer immunoglobulin-like receptors and natural killer cells in MS, Wellcome Trust,
£297,230 - Refining the trial design for adaptive treatment selection in MS, MS Society‟, Lead applicant Dr Tim Friede,
£27,600
websites: http://www.warwick.ac.uk/go/ms_adaptive
http://www2.warwick.ac.uk/fac/med/research/themes/methodology/medicalstats/sequential/ms-adaptive - Epilepsy and Multiple Sclerosis‟, Biogen Idec, Dr Roberta Magilozzi,
£4,000 - 2009-Multiple Sclerosis Clinical trials unit development, Berkeley Homes,
£450,000 - A baseline-to-treatment, MRI-controlled phase II(a) trial of autologous mesenchymal stem cell transplantation in
treatment-refractory highly active relapsing-remitting multiple sclerosis‟, MS Society and UK Stem Cell Foundation,
Lead applicant Paolo Muraro
£527,000 - Immunological imaging of Multiple Sclerosis and Clinically Isolated Syndromes: the role of activated microglia‟, FISMs,
Dr Paolo Giannetti.
€ 50,000 - Dissecting the role of T-and B-cell immune repertoire perturbations in blood lymphocytes of multiple sclerosis patients‟, BRC with Dr Paolo Muraro,
£52,000 - A study to characterize the novel TSPO PET radioligand [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis Study: EMI115241, Dr Alessandro Colasanti, GSK and Wellcome.
- What are the English population norms, criterion validity and reproducibility of the Brief International Cognitive Assessment for Multiple Sclerosis? HTA, Dr Dawn Langdon
- Dr Wakerley, MRC clinical fellow
£200,000
CONSULTANCY
MSTC was involved in updating the script of the MS play "Duet for One‟ starring Juliet Stephenson staged in 2010.
